Anzeige
Mehr »
Samstag, 05.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40HU3 | ISIN: US3207033099 | Ticker-Symbol:
NASDAQ
03.07.25 | 17:40
0,248 US-Dollar
-0,88 % -0,002
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CALIDI BIOTHERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CALIDI BIOTHERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur CALIDI BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoCalidi Biotherapeutics, Inc. - S-1, General form for registration of securities1
27.06.Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Shareholder Letter from CEO143SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted...
► Artikel lesen
CALIDI BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
14.05.Calidi Biotherapeutics, Inc. - 8-K, Current Report6
14.05.Calidi Biotherapeutics GAAP EPS of -$0.18 misses by $0.032
14.05.Calidi Biotherapeutics, Inc. - 10-Q, Quarterly Report2
14.05.Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights100Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered...
► Artikel lesen
02.05.Calidi Biotherapeutics, Inc. - 8-K, Current Report1
25.04.Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711141SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
► Artikel lesen
23.04.Calidi Biotherapeutics appoints new CEO2
23.04.Calidi Biotherapeutics names Poma as CEO4
23.04.Calidi Biotherapeutics, Inc. - 8-K, Current Report1
21.04.US FDA clears Calidi's CLD-201 for clinical development in solid tumours1
10.04.Calidi Biotherapeutics Names Guy Travis Clifton Chief Medical Officer1
10.04.Calidi Biotherapeutics, Inc. - 8-K, Current Report-
31.03.Calidi Biotherapeutics, Inc. - 8-K, Current Report2
31.03.Calidi Biotherapeutics, Inc. - 10-K, Annual Report2
31.03.Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement1
31.03.Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights78Announced demonstrated ability to deliver transient gene therapy (payload) to tumors using systemic antitumor virotherapy platform Filed IND in March 2025 for CLD-201 company sponsored Phase 1 trial...
► Artikel lesen
28.03.Calidi Biotherapeutics sinks after pricing $3.9M registered direct offering4
28.03.Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement1
Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1